Innate host defense functions of secretory leucoprotease inhibitor

Experimental Lung Research

Volumn 33, Issue 10, 2007, Pages 485-491

  Weldon, Sinead ^a   Taggart, Clifford C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antimicrobial; Antiprotease; Immunomodulation; Secretory leucoprotease inhibitor

Indexed keywords

I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CHRONIC LUNG DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG MECHANISM; EMPHYSEMA; ENZYME INHIBITION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN;

HUMANS; IMMUNITY, NATURAL; PNEUMONIA; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERINE PROTEINASE INHIBITORS;

EID: 37149048392     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140701756547     Document Type: Conference Paper

References (38)

1. Doumas S, Kolokotronis A, Stefanopoulos P: Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73:1271-1274.
2. Hochstrasser K, Reichert R, Schwartz S, Werle E: Isolation and characterisation of a protease inhibitor from human bronchial secretion. Hoppe-Seyler's Z Physiol Chem. 1972;353:221-226.
3. Ohlsson K, Tegner H: Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Clin Lab Invest. 1976;36:437-445.
4. Tegner H: Quantitation of human granulocyte protease inhibitors in non-purulent bronchial lavage fluids. Acta Oto-Laryngol. 1978;85:282-289.
5. Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 1986;83:6692-6696.
6. Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J. 1999;340:569-577.
7. Clauss A, Lilja H, Lundwall A: The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun. 2005;333:383-389.
8. Ranganathan S, Simpson KJ, Shaw DC, Nicholas KR: The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J Mol Graph Model. 1999;17:106-113, 134-136.
9. Clauss A, Lilja H, Lundwall A: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 2002;368:233-242.
10. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456-464.
11. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, McElvaney NG: Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276:33345-33352.
12. McElvaney NG, Taggart CC: Antiproteases. In: Barnes P, ed. Chronic Obstructive Pulmonary Disease Cellular and Molecular Mechanisms. Boca Raton, FL: Taylor Francis; 2005:343-365.
13. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F, Shiloh MU, Ding A: Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med. 2000;28:1276-1282.
14. Sponer M, Nick HP, Schnebli HP: Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol Chem Hoppe Seyler. 1991;372:963-970.
15. Draper D, Donohoe W, Mortimer L, Heine RP: Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis. 1998;178:815-819.
16. Greene C, Taggart C, Lowe G, Gallagher P, McElvaney N, O'Neill S: Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. J Infect Dis. 2003;188:769-776.
17. Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001;56:36-41.
18. Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA: Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192:1587-1600.
19. Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88:417-426.
20. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH: Antibacterial activity of antileukoprotease. Infect Immun. 1996;64:4520-4524.
21. Williams SE, Brown TI, Roghanian A, Sallenave J-M: SLPI and elafin: one glove, many fingers. Clin Sci. 2006;110:21-35.
22. Wiedow O, Harder J, Bartels J, Streit V, Christophers E: Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun. 1998;248:904-909.
23. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood. 1997;90:1141-1149.
24. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004;200:1337-1346.
25. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997;99:894-900.
26. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG: Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296-1301.
27. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA: Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol. 1999;154:239-247.
28. Mulligan MS, Lentsch AB, Huber-Lang M, Guo RF, Sarma V, Wright CD, Ulich TR, Ward PA: Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol. 2000;156:1033-1039.
29. Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J, Takai T, Nukiwa T: Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003;197:669-674.
30. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM, Santini PA, Cerutti A: Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303.
31. Ding A, Thieblemont N, Zhu J, Jin F, Zhang J, Wright S. Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect Immun. 1999;67:4485-4489.
32. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill SJ, McElvaney NG: Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202:1659-1668.
33. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol. 2004;172:4535-4544.
34. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC: Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun. 2004;72:3684-3687.
35. Taggart CC, Greene CM, McElvaney NG, O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem. 2002;277:33648-33653.
36. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR: Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J Biol Chem. 1999;274:787-794.
37. Hu X: Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation. Cytokine. 2003;21:286-294.
38. Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem. 1997;272:29419-29422.